Akeso, Inc. (9926.HK)
Develops antibody drugs to treat cancers, immune diseases, and high cholesterol
95.10-0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-39.2%
The outlook
Akeso trades near its 52-week low with strong analyst backing—the consensus is "Strong Buy" with an average price target roughly 78% above current levels. However, the stock sits below both its 50- and 200-day moving averages, signaling weakness in near-term momentum. Overall sentiment is neutral despite the bullish analyst view.
What’s behind the score
Analyst consensusStrong Buy — 1.4 avg of 20 analysts
Price trendBelow its 50- & 200-day averages
52-week range15% of the way from its 52-week low to high
Price targetAvg target +78% vs current price
Analyst price target
~12-month · 20 analysts169.42average target+78.2% vs now
Now 95.10
Low 129.00High 225.95
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$87.60B
52-wk high
179.00
52-wk low
80.20
50-day avg
98.51
200-day avg
114.08
Trailing P/E
—